Aktis Oncology is a clinical-stage company developing targeted alpha radiopharmaceuticals for solid tumors. Its approach uses miniprotein radioconjugates designed to deliver actinium-225 to tumor markers such as Nectin-4 and B7-H3. Lead candidates are in early clinical development for cancers including urothelial, breast, lung, and other solid tumors. The company collaborates with partners on discovery and manufacturing of these precision radiotherapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0.9 | — | -12.1 | — |
| Q1 2025 | 1.4 | — | -15 | — |
| Q4 2025 | 1.9 | 100.4% | -15.1 | — |
| Q1 2026 | 3.2 | 123% | -18.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Burke & Herbert Financial Services Corp. (BHRB), Amalgamated Financial Corp. (AMAL), WEBTOON Entertainment Inc. (WBTN), Azenta, Inc. (AZTA), Sigma Lithium Corporation (SGML), Dorchester Minerals, L.P. (DMLP)